METTL7AP1

Across TCGA pan-cancer cohorts, METTL7AP1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of METTL7AP1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where METTL7AP1 RNA is repressed in tumor relative to normal tissue. In most cancer types METTL7AP1 is over-expressed in tumor, although a few such as KIRC and BRCA show the opposite, repressed pattern.

KIRC, BRCA, and KICH are the cancer types where METTL7AP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL7AP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	−0.031	.001	7	view →
BRCA	All	II,III,IV	−0.029	.015	4	view →
KICH	All	II,III,IV	−0.082	.027	2	view →
THCA	All	All	−0.045	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

METTL7AP1–KIRC

Open the KIRC breakdown →